Analysts Set Merck & Co., Inc. (NYSE:MRK) Target Price at $128.47

Merck & Co., Inc. (NYSE:MRK) has been given a consensus rating of “Moderate Buy” by the nineteen analysts that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $128.4706.

Several research analysts have recently issued reports on MRK shares. TD Cowen raised their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Friday, February 13th. Citigroup lifted their price target on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, March 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. Finally, Barclays assumed coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price target on the stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: UBS raised its price target on MRK to $145, which is a direct positive signal from a major sell-side firm and can lift investor sentiment. UBS Boosts MRK Price Target
• Positive Sentiment: Zacks highlights Keytruda as the primary growth driver heading into Q1 results, noting new indications and uptake that could sustain revenue growth — this supports medium-term earnings expectations. Will Keytruda Continue to Aid Merck’s Top Line?
• Positive Sentiment: Market chatter and technical traders are bullish on MRK; an options/technical piece highlights a bullish diagonal trade targeting $130, reflecting some traders positioning for a near-term rebound. Bullish Diagonal Trade Targets $130
• Neutral Sentiment: Zacks/Yahoo attention pieces note MRK is a trending stock and recap key facts (pipeline, Keytruda dependence, valuation) — useful for retail interest but not new company-specific catalysts. Merck Is a Trending Stock
• Neutral Sentiment: Industry reports cite Merck among major players in the animal-health market outlook — this is incremental, long-term relevance rather than an immediate stock driver. Animal Health Market Intelligence Report
• Neutral Sentiment: Coverage of Merck KGaA (XTRA:MRK) valuation can create ticker/name confusion for casual readers but has no direct impact on U.S.-listed Merck & Co. fundamentals. Assessing Merck KGaA Valuation
• Neutral Sentiment: Other healthcare staffing and small-cap biotech headlines in the feed (Soleo Health, Summit Therapeutics) are peripheral and unlikely to move MRK stock materially. Soleo Health Appointment Summit Therapeutics BLA Acceptance

Merck & Co., Inc. Stock Down 2.1%

Shares of Merck & Co., Inc. stock opened at $115.42 on Tuesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The stock has a market capitalization of $285.07 billion, a price-to-earnings ratio of 15.85, a P/E/G ratio of 2.37 and a beta of 0.26. The company’s 50 day moving average price is $119.18 and its 200-day moving average price is $105.58.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter last year, the business earned $1.72 earnings per share. The business’s revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were paid a $0.85 dividend. The ex-dividend date was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Insider Buying and Selling

In related news, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the transaction, the chief financial officer owned 90,192 shares in the company, valued at $10,787,865.12. The trade was a 31.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 over the last quarter. 0.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. bought a new position in Merck & Co., Inc. in the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Abound Financial LLC bought a new position in Merck & Co., Inc. in the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the 4th quarter worth approximately $31,000. Finally, High Note Wealth LLC boosted its position in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.